Imagine trying to understand a city's traffic by looking at a blurred photo of the whole town; that is how we currently study proteins in groups of cells. This technology acts like a high-resolution camera that looks at every single car individually. It can spot tiny changes in protein behavior and interactions that were previously invisible, helping us see exactly why a specific cell becomes cancerous.
Current proteomics methods are slow, lack sensitivity, and cannot analyze individual cells in parallel. This masks cellular heterogeneity, making it difficult to identify rare cancer cells or precise drug targets.
A single-cell proteomics tool integrating digital PCR and NGS. It includes 1-million-compartment devices and a validated panel of 41 molecular markers.
If you are a drug discovery firm dealing with drug resistance in cancer—this project developed a tool that measures over 50 targets in hundreds of single cells. This allows you to identify the specific subpopulations of cells causing resistance. It enables more precise drug targeting based on individual cellular responses.
If you are a diagnostics developer dealing with imprecise biomarkers—this project developed a high-sensitivity assay capable of detecting 10 proteoform molecules per single cell. This allows for the creation of ultra-sensitive diagnostic tests. It provides patient-specific insights for precision medicine.
If you are a crop science company dealing with complex plant stress responses—this project developed a multiplexed analysis tool for proteins and interactions. This helps in understanding biological pathways at a single-cell level. It accelerates the development of hardier, more productive crop varieties.
Based on available project data, specific pricing for the PICO-NGS tool is not provided.
The project demonstrated technical feasibility for high-resolution analysis using 1-million-compartment devices (QbMD and SbMD).
Based on available project data, specific licensing terms are not mentioned, though the technology was developed by Actome GmbH.
The technology integrates digital PCR and NGS readouts with high-multiplex antibody panels to provide protein quantification.
The project was terminated prematurely, though it achieved milestones in marker validation and device development.
The project was led by a single partner, Actome GmbH, a German SME. This 100% industry-led structure suggests a strong focus on commercial application rather than academic exploration, though the lack of a broader consortium may have contributed to the resource constraints that led to the project's termination.
Contact Actome GmbH in Germany for licensing of the validated marker panels.
Contact us to find similar high-sensitivity proteomics technologies.
